We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Signature Odor of Parkinson's Disease Discovered

By LabMedica International staff writers
Posted on 02 Apr 2019
Parkinson's disease is a neurodegenerative disorder that leads to progressive brain cell death and extensive loss of motor function. More...
Despite many investigations being conducted on this disease, there are no definitive diagnostic tests currently available.

Volatile organic compounds (VOCs) are often associated with characteristic odors, although some volatiles may also be odorless. The term “volatilome” describes the entirety of the volatile organic and inorganic compounds that may originate from any organism, or object, which may be analytically characterized.

A team of biochemists and other scientists working with the University of Manchester (Manchester, UK) collected sebum samples, an oily or waxy matter secreted by sebaceous glands, using gauze to swab the upper backs of more than 60 subjects, both with and without Parkinson's disease (PD). There were 43 PD subjects and 21 controls, and an independent validation cohort of 31.

A dynamic headspace (DHS) gas chromatography–mass spectrometry (GC–MS) method was developed for the analysis of gauze swabs, which contained sampled participant sebum. DHS is a sample preparation capability for subsequent GC application using the GERSTEL MultiPurpose sampler that concentrates VOCs from liquid or solid samples. The GC analysis was performed on an Agilent GC 7890B coupled to an Agilent MSD 5977B.

The team showed that the data revealed the presence of hippuric acid, eicosane and octadecanal, which indicate the altered levels of neurotransmitters found in Parkinson's patients, along with several other biomarkers for the disease. There were no significant differences observed between PD participants on medication and drug naïve PD participants for all measured volatiles, indicating that the majority of the analyzed volatilome and by inference sebum are unlikely to contain drug metabolites associated with PD medication.

The authors concluded that their study highlights the potential of comprehensive analysis of sebum from PD patients and raises the possibility that individuals can be screened noninvasively based on targeted analysis for these volatile biomarkers. The study was published on March 20, 2019, in the journal ACS Central Science.

Related Links:
University of Manchester


Gold Member
Blood Gas Analyzer
Stat Profile pHOx
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Automatic CLIA Analyzer
Shine i9000
Automatic Hematology Analyzer
DH-800 Series
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The Monarch Mag Cell-free DNA (cfDNA) Extraction Kit provides isolation of low-abundance cfDNA from a range of biofluids (Photo courtesy of New England Biolabs)

New Extraction Kit Enables Consistent, Scalable cfDNA Isolation from Multiple Biofluids

Circulating cell-free DNA (cfDNA) found in plasma, serum, urine, and cerebrospinal fluid is typically present at low concentrations and is often highly fragmented, making efficient recovery challenging... Read more

Immunology

view channel
Image: The TmS computational biomarker analyzes tumor gene expression and microenvironment data to guide treatment decisions (Photo courtesy of MD Anderson Cancer Center)

New Biomarker Predicts Chemotherapy Response in Triple-Negative Breast Cancer

Triple-negative breast cancer is an aggressive form of breast cancer in which patients often show widely varying responses to chemotherapy. Predicting who will benefit from treatment remains challenging,... Read more

Pathology

view channel
Image: The innovative classifier can guide treatment for PDAC and other immunotherapy-resistant cancers (Photo courtesy of Adobe Stock))

Single Sample Classifier Predicts Cancer-Associated Fibroblast Subtypes in Patient Samples

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest cancers, in part because of its dense tumor microenvironment that influences how tumors grow and respond to treatment.... Read more

Industry

view channel
Image: QuidelOrtho has entered into a strategic supply agreement with Lifotronic to expand its global immunoassay portfolio (Photo courtesy of QuidelOrtho)

QuidelOrtho Collaborates with Lifotronic to Expand Global Immunoassay Portfolio

QuidelOrtho (San Diego, CA, USA) has entered a long-term strategic supply agreement with Lifotronic Technology (Shenzhen, China) to expand its global immunoassay portfolio and accelerate customer access... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.